5

completion of treatment, whichever is longer 84 Lymphoma Defer permanently 59–60 Malaria Local criteria depending on endemicity Refer to Section 7.4.1 79–81, 87 Malabsorption syndromes Defer permanently except treated coeliac disease 55–56 Malignant diseases Accept malignancy “in situ” (e.g. basal cell carcinoma, cervical carcinoma in situ), if successfully treated, regularly monitored and in good health Defer if current diagnosis of malignancy or less than 5 years since completion of treatment Defer permanently if malignant melanoma, lymphoproliferative or haematological disorders Also refer to Section 5.9 59–60 Measles Defer for 14 days following full recovery Also refer to Section 7.3.6 78 Medications Take account of indication for treatment Accept long-term low-dose antibiotics for acne Defer for 14 days following antibiotic use Retinoids, dutasteride, finasteride, aspirin and non-steroidal anti-inflammatory drugs: also refer to Section 7.7 64–65 Menstruation Accept 46–47 Minor illnesses Defer for 14 days after full recovery from acute infection and completion of antibiotic treatment 41 12 Multiple sclerosis Defer permanently Also refer to Section 5.8.4 58–59 Mumps Defer for 14 days following full recovery Also refer to Section 7.3.6 78 Musculoskeletal disorders Accept acute or chronic simple disorders (e.g. mild rheumatoid arthritis, back pain, sciatica, frozen shoulder, osteoarthritis) if mobile Defer permanently if systemic disease affecting joints: e.g. severe rheumatoid arthritis, psoriatic arthropathy, ankylosing spondylitis 60 Myelodysplastic syndrome Defer permanently 59–60 Nephritis Refer to Section 5.7 57–58 Peptic ulcer Defer until completion of treatment and full recovery 55 Piercing Defer for 12 months following last acupuncture, piercing, tattoo, scarification or invasive cosmetic procedure 68, 90 Platelet disorders Refer to Section 5.1.4 51 Polycythaemia Accept secondary erythrocytosis Defer permanently polycythaemia rubra vera 51, 59–60 Pregnancy and lactation D diseases Accept mild common skin disease (e.g. acne, eczema, psoriasis) if lesions not infected, venepuncture site is unaffected Defer if generalized skin disease and on systemic medication Defer if contagious skin disease Defer permanently if systemic disease affecting skin (e.g. scleroderma, systemic lupus erythematosus, dermatomyositis, systemic cutaneous amyloidosis) Also refer to Sections 5.11 and 6.2 60–61, 64–65 Streptococcus infection Defer for 28 days following full recovery Defer for 14 days following full healing if recent superficial but significant wounds 85 Stroke Defer permanently Also refer to Section 5.8.1 58–59 Surgery Defer following minor surgery until treatment is complete and successful and normal activity resumed Defer for 12 months following major surgery Defer permanently following neurosurgical procedure, dura mater graft or corneal transplant Also refer to Sections 6.4 and 7.7 67, 86–87 Syphilis Defer permanently if has ever had a diagnosis of syphilis Also refer to Section 7.5.1 83–84 Systemic lupus erythematosus Defer permanently Also refer to Section 5.11 57, 60–61 Tattoos Refer to Section 7.9.5 68, 90 Thalassaemia Accept thalassaemia trait provided well and haemoglobin above required lower limit Defer permanently thalassaemia major Also refer to Section 5.1.2 50 Thrombocytopenia Accept past history of acute autoimmune thrombocytopenia more than 5 years previously, if well and not on treatment, except prophylactic antibiotics following splenectomy Defer permanently if thrombocytopenia of unknown cause or associated with longterm haematological or systemic disease 51, 59–60 Thrombosis Refer to Section 5.2.2 52–53, 54 15 Thyroid disorders Accept if benign disorder and euthyroid (with or without treatment) Defer if under investigation for thyroid disease, if hyper- or hypo-thyroid, or with a history of malignant thyroid tumours (also refer to Section 5.9) Defer permanently if history of thyrotoxicosis due to Graves’ disease 56–57 Transient cerebral ischaemic episodes Defer permanently Also refer to Section 5.8.1 58–59 Transplantation Defer for 12 months following transplantation of allogeneic tissues Defer permanently if transplanted with allogeneic cells or tissue sourced since 1980 from a country in which risk of vCJD has been identified Defer permanently following stem cell or organ transplantation, dura mater graft, corneal transplant or xenograft 65–67 Tuberculosis Defer for 2 years following confirmation of cure Also refer to Section 7.5.6 85 Ulcerative colitis Refer to Section 5.4 55–56 Urinary tract diseases Accept lower urinary tract infections 14 days after full recovery and completion of treatment Also refer to Section 5.7 57–58 Vaccination Refer to Section 6.1 63–64 Variant Creutzfeldt-Jakob disease (vCJD) Defer permanently

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25